Clinical trial NCT06540391: A Phase 1b Trial to Evaluate Safety of MB097 in Combination with Pembrolizumab in Melanoma Patients
Official title: A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an AntiPD1Containing Immunotherapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Melanoma
Lead sponsor: Microbiotica Ltd
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2024-08-06
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.


Eligibility criteria: Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Must have primary resistant cutaneous melanoma and have experienced disease progression as defined by RECIST v1.1 after receiving at least 6 weeks of exposure to PD-1/PD-L1 inhibitor therapy, generally correlating with 2 complete cycles of PD-1/PD-L1 inhibitor therapy.
* Must have histological or cytological confirmation of Stage III (unresectable) or Stage IV cutaneous melanoma
* Must have radiographically measurable disease per RECIST v1.1
* Must be at least 18 years of age at time of informed consent
* Must provide written informed consent, according to local guidelines, signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analysis
* Must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at time of informed consent.
* Must have acceptable organ function, as evidenced by laboratory data prior to first dose of any study drug
* Female patients must not be lactating or pregnant
* Male patients, and female patients of childbearing potential who are at risk of pregnancy must agree to use a highly effective method of contraception
* Must have life expectancy ≥12 weeks after the start of any study drug per Investigator's judgment
* Must be willing and able to comply with the Protocol, scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guidelines, and all other study procedures.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following

* Any treatment for melanoma following the failure of an aPD-1-containing treatment, i.e., no intervening treatments between aPD-1 failure and enrollment into study;
* Prior therapy with any of the following:

  * Radiation therapy to target lesions within 6 weeks of the first dose of MB097
  * Major invasive surgery, excluding placement of vascular access, within 28 days of the first dose of any study drug
  * Probiotic supplement use within 7 days of the first dose of any study
  * LBP use, including FMT, within 6 months of start of therapy with MB097.
* Active, uncontrolled infection requiring systemic antimicrobial, antiviral, or antifungal therapy.
* Active, uncontrolled, symptomatic brain metastases or leptomeningeal metastases
* Ocular, uveal, acral, or mucosal melanoma
* Prior treatment-related toxicities that have not resolved to Grade 2 or less per NCI CTCAE v5.0;
* Patients with a history of immune-related colitis may be included if symptoms have resolved to Grade 1 or less for at least 14 days prior to screening
* Any history of CTCAE v5.0 immune-related toxicity Grade 3 or greater from prior CPI that is recurrent or steroid-refractory
* Known hypersensitivity to any of the ingredients of the study drug(s) or known hypersensitivity to vancomycin (oral or IV)
* Significant medical conditions which, in the Investigator's opinion, could compromise or interfere with the patient's safety or integrity of the study outcomes
* Severe colitis of any etiology (except colitis associated with treatment with an aPD-1 inhibitor)
* History of another malignancy within 3 years before the first dose of any study drug, or any evidence of residual disease from a previously diagnosed malignancy
* Clinically significant (i.e., active) cardiovascular disease
* Any clinically significant safety concern related to prior CPI therapy
* Active autoimmune disease that required systemic treatment in the past 2 years prior to screening
* History of investigational agent or device use within 4 weeks prior to the first dose of study treatment or current participation in a study of an investigational agent
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or, in the opinion of the Investigator, is considered to not be in the best interest of the patient to participate in the study.

Primary outcomes:
measure: Safety and tolerability of MB097 in combination with pembrolizumab
timeFrame: From Visit 1 to 30 days after the last dose of study treatment
Secondary outcomes:
measure: Best objective response rate (b-ORR) by RECIST v1.1 and iRECIST
timeFrame: Up to Week 24 or Week 105(for patients in extended treatment)
measure: Overall response rate (ORR) by RECIST v1.1 and iRECIST
timeFrame: Up to Week 24 or Week 105(for patients in extended treatment)
measure: Disease control rate (DCR) by RECIST v1.1 and iRECIST
timeFrame: Up to Week 24 or Week 105(for patients in extended treatment)
measure: Duration of response
timeFrame: Up to Week 24 or Week 105(for patients in extended treatment)
measure: Progression-free survival,
timeFrame: Up to Week 24 and Week 36, and Week 105(for patients in extended treatment)
measure: Time to progression
timeFrame: Up to Week 24 or Week 105(for patients in extended treatment)
measure: Quantification of MB097 strains at baseline and over the intervention period in patients treated with MB097 with and without vancomycin preconditioning and correlation to efficacy measures
timeFrame: Up to Week 24 or Week 105(for patients in extended treatment)
Other outcomes:
Locations:
city: Dijon
country: France
facility: Centre Georges Francois Leclerc
city: Lille
country: France
facility: CHU de Lille - Hopital Claude Huriez
city: Lyon
country: France
facility: Centre Leon Berard
city: Marseille
country: France
facility: AP-HM - Hopital de la Timone
city: Pierre-Benite Cedex
country: France
facility: HCL Centre Hospitalier Lyon Sud
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Madrid
country: Spain
facility: Hospital Universitario Ramon y Cajal
city: Madrid
country: Spain
facility: South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
city: Valencia
country: Spain
facility: Consorcio Hospital General Universitario de Valencia
city: Brighton
country: United Kingdom
facility: Sussex Cancer Centre
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: London
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
city: Newcastle
country: United Kingdom
facility: Freeman Hospital
city: Sutton
country: United Kingdom
facility: Royal Marsden Hospital - Surrey
Study officials:
References: